Pdt Partners, LLC Chemo Centryx, Inc. Transaction History

Pdt Partners, LLC

$1.01 Billion
Q1 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2019 Feb 14, 2020	SELL	$6.81 - $39.55 $86,487 - $502,284	-12,700 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$6.47 - $8.96 $229,723 - $318,133	-35,506 Reduced 73.65%	12,700 $86,000
Q2 2019 Aug 14, 2019	BUY	$8.31 - $14.85 $235,887 - $421,532	28,386 Added 143.22%	48,206 $448,000
Q1 2019 May 15, 2019	BUY	$10.01 - $13.89 $3,513 - $4,875	351 Added 1.8%	19,820 $275,000
Q4 2018 Feb 14, 2019	BUY	$9.15 - $12.26 $15,143 - $20,290	1,655 Added 9.29%	19,469 $212,000

Q3 2018 Nov 14, 2018	BUY	$10.49 - $13.72 $186,868 - $244,408	17,814 New	17,814 $225,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.